PACIRA BIOSCIENCES, INC. Increase (Decrease) in Accrued Liabilities
PACIRA BIOSCIENCES, INC. (PCRX) reported Increase (Decrease) in Accrued Liabilities of $1.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $11.87M.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$10.30M, a 319.16% decline year-over-year.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $7.53M, a 32.68% decline year-over-year.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-06-30 was -$19.38M.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $11.72M.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2023 was -$22.04M.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2022 was -$19.86M, a 464.28% decline from fiscal 2021.
- PACIRA BIOSCIENCES, INC. increase (decrease) in accrued liabilities for fiscal 2021 was $5.45M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $11.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.56M 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | -$10.30M 10-Q · filed 2026-04-30 | ||||
| 2025-09-30 | $7.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$11.85M derived: sum of 2 quarters · filed 2026-08-04 | -$7.14M 10-Q · filed 2025-11-06 | -$7.97M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | -$19.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$14.68M 10-Q · filed 2026-08-04 | -$15.50M derived: sum of 3 quarters · filed 2026-08-04 | -$4.32M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $4.70M 10-Q · filed 2026-04-30 | $3.88M derived: sum of 2 quarters · filed 2026-04-30 | $15.06M derived: sum of 3 quarters · filed 2026-04-30 | $12.95M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | -$826.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $10.36M derived: sum of 2 quarters · filed 2025-11-06 | $8.25M derived: sum of 3 quarters · filed 2025-11-06 | $11.72M 10-K · filed 2025-02-27 | |
| 2024-09-30 | $11.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.07M derived: sum of 2 quarters · filed 2025-11-06 | $12.55M 10-Q · filed 2025-11-06 | $16.66M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$2.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.36M 10-Q · filed 2025-08-05 | $5.48M derived: sum of 3 quarters · filed 2025-08-05 | $10.09M derived: sum of 4 quarters · filed 2025-08-05 | |
| 2024-03-31 | $3.47M 10-Q · filed 2025-05-08 | $7.59M derived: sum of 2 quarters · filed 2025-05-08 | $12.20M derived: sum of 3 quarters · filed 2025-05-08 | $6.55M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $8.73M derived: sum of 2 quarters · filed 2025-02-27 | $3.08M derived: sum of 3 quarters · filed 2025-02-27 | -$22.04M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $4.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.04M derived: sum of 2 quarters · filed 2024-11-06 | -$26.16M 10-Q · filed 2024-11-06 | -$22.45M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | -$5.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | -$30.77M 10-Q · filed 2024-07-30 | -$27.07M derived: sum of 3 quarters · filed 2025-02-27 | -$31.59M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$25.12M 10-Q · filed 2024-05-07 | -$21.42M derived: sum of 2 quarters · filed 2025-02-27 | -$25.94M derived: sum of 3 quarters · filed 2025-02-27 | -$35.82M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$819.00K derived: sum of 2 quarters · filed 2025-02-27 | -$10.70M derived: sum of 3 quarters · filed 2025-02-27 | -$19.86M 10-K · filed 2025-02-27 | |
| 2022-09-30 | -$4.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$14.40M derived: sum of 2 quarters · filed 2023-11-02 | -$23.56M 10-Q · filed 2023-11-02 | -$1.07M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | -$9.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$19.04M 10-Q · filed 2023-08-02 | $3.45M derived: sum of 3 quarters · filed 2024-02-29 | $4.55M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | -$9.16M 10-Q · filed 2023-05-03 | $13.32M derived: sum of 2 quarters · filed 2024-02-29 | $14.43M derived: sum of 3 quarters · filed 2024-02-29 | $14.32M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $22.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $23.59M derived: sum of 2 quarters · filed 2024-02-29 | $23.48M derived: sum of 3 quarters · filed 2024-02-29 | $5.45M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $993.00K derived: sum of 2 quarters · filed 2022-11-03 | -$17.03M 10-Q · filed 2022-11-03 | -$6.58M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | -$113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$18.14M 10-Q · filed 2022-08-03 | -$7.68M derived: sum of 3 quarters · filed 2023-02-28 | -$2.67M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | -$18.03M 10-Q · filed 2022-05-04 | -$7.57M derived: sum of 2 quarters · filed 2023-02-28 | -$2.56M derived: sum of 3 quarters · filed 2023-02-28 | $674.00K derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $10.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $15.47M derived: sum of 2 quarters · filed 2023-02-28 | $18.70M derived: sum of 3 quarters · filed 2023-02-28 | -$6.00M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $5.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $8.25M derived: sum of 2 quarters · filed 2021-11-03 | -$16.45M 10-Q · filed 2021-11-03 | $1.58M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $3.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$21.47M 10-Q · filed 2021-08-03 | -$3.43M derived: sum of 3 quarters · filed 2022-02-28 | -$1.27M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | -$24.70M 10-Q · filed 2021-05-04 | -$6.66M derived: sum of 2 quarters · filed 2022-02-28 | -$4.50M derived: sum of 3 quarters · filed 2022-02-28 | $2.51M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | $18.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $20.20M derived: sum of 2 quarters · filed 2022-02-28 | $27.21M derived: sum of 3 quarters · filed 2022-02-28 | $22.04M 10-K · filed 2022-02-28 | $20.21M 10-K · filed 2020-02-21 |
| 2019-09-30 | $2.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $9.17M derived: sum of 2 quarters · filed 2020-10-30 | $4.00M 10-Q · filed 2020-10-30 | $9.28M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-06-30 | $7.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.84M 10-Q · filed 2020-08-06 | $7.12M derived: sum of 3 quarters · filed 2021-03-01 | $9.35M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-03-31 | -$5.17M 10-Q · filed 2020-05-07 | $108.00K derived: sum of 2 quarters · filed 2021-03-01 | $2.34M derived: sum of 3 quarters · filed 2021-03-01 | $7.66M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2018-12-31 | $5.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $7.51M derived: sum of 2 quarters · filed 2021-03-01 | $12.83M derived: sum of 3 quarters · filed 2021-03-01 | $5.20M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $7.55M derived: sum of 2 quarters · filed 2019-11-08 | -$71.00K 10-Q · filed 2019-11-08 | $1.93M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-06-30 | $5.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$2.30M 10-Q · filed 2019-08-08 | -$300.00K derived: sum of 3 quarters · filed 2020-02-21 | -$7.06M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-03-31 | -$7.62M 10-Q · filed 2019-05-02 | -$5.62M derived: sum of 2 quarters · filed 2020-02-21 | -$12.38M derived: sum of 3 quarters · filed 2020-02-21 | -$1.68M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2017-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | -$4.75M derived: sum of 2 quarters · filed 2020-02-21 | $5.95M derived: sum of 3 quarters · filed 2020-02-21 | $3.65M 10-K · filed 2020-02-21 | |
| 2017-09-30 | -$6.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $3.94M derived: sum of 2 quarters · filed 2018-11-01 | $1.64M 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | $10.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $8.40M 10-Q · filed 2018-08-02 | |||
| 2017-03-31 | -$2.30M 10-Q · filed 2018-05-03 | ||||
| 2016-12-31 | $1.06M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |